Heart Failure Trial Update—Analysis of Recent Data

Divyanshu Mohananey, Holly Mewhort, Shashank Shekhar, Akanksha Mohananey, Rahul Chaudhary, Nunzio Gaglianello, Harish Ramakrishna

Research output: Contribution to journalReview articlepeer-review


The prevalence of heart failure (HF) continues to increase, and its economic effect is significant in the United States and globally. During the past 2 years, a number of high-quality clinical trials were published with the aim of addressing different stages of the disease process and improving outcomes for patients with preserved and depressed ejection fraction (EF). In this review, data from these trials are summarized and critically appraised. There are several important findings from these studies, including, but not limited to, the benefit of dapagliflozin in HF with reduced EF, sacubitril-valsartan in acute decompensated HF, thoracotomy in left ventricular assist device implantation, and the overall risk-benefit ratios of centrifugal pumps as opposed to continuous flow pumps. Effective therapies for HF with preserved EF continue to evolve for this varied group of high morbidity and mortality conditions.

Original languageEnglish (US)
Pages (from-to)2792-2800
Number of pages9
JournalJournal of Cardiothoracic and Vascular Anesthesia
Issue number9
StatePublished - Sep 2021


  • VAD
  • dapagliflozin
  • heart failure
  • trials
  • ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Heart Failure Trial Update—Analysis of Recent Data'. Together they form a unique fingerprint.

Cite this